Oxford BioMedica plc
https://www.oxb.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oxford BioMedica plc
Newly Unveiled Ampersand's CEO On ‘Programmable’ Medicines And Flagship’s Winning Formula
Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.
Draft Biosimilar Red Tape Elimination Act: Pharmacist As Ally, Would Patients Benefit?
If the bill on the Biosimilar Red Tape Elimination Act is passed, all biosimilars would be deemed interchangeable on US FDA approval. Scrip takes a look at what empowering pharmacists could mean, what the generics substitution experience shows and where possible pain points lie
Asia Deal Watch: Lotus Brings Corium’s Donepezil Patch To 10 Markets
Plus deals from Huadong/Arcutis, SK Bioscience/Novavax, NeuroBio/MThera, CASI/Mundipharma/Acrotech, Amarin/Lotus and Synergy/Livzon.
Healthcare Reform: GE HealthCare On ‘Building A Bridge To The Future State’
System interoperability and building trust in AI capabilities are central to the strategic collaboration and organic growth plans at GE HealthCare, according to US and Canada regional president and CEO Catherine Estrampes, who spoke to In Vivo as the company released the findings of a major survey of clinicians and patients on future healthcare system needs.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Oxxon Therapeutics Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice